Emerging evidence indicates that a Tie2 agonist could be a promising drug for several vascular diseases, including vascular retinopathies, sepsis, glaucoma, and cancers, by enhancing vascular stability, normalization, and rejuvenation while reducing vascular leakage and inflammation3,16–19. This evidence concerns the gene TEK and Sepsis.